US FDA approves Shire's Gaucher's therapy Vpriv
01 March 2010
Asher Mullard
Please Login to read the full article.
01 March 2010
Asher Mullard
asher.mullard@informa.com
The US FDA has approved Shire's Vpriv (velaglucerase alfa) for the treatment of type I Gaucher's disease, the most prevalent type of the rare lysosomal storage disease.
"We forecast a rapid launch with $70m 2010E sales and $220m at peak," wrote Jefferies analysts.
Initially Vpriv...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Protalix CEO confident data submission will address US FDA concerns for Gaucher's drug
- Protalix looks to February for US FDA decision on Gaucher's drug
- Shire gets EU nod to make Replagal in Lexington
- New Zealand's PHARMAC seeks info to support use of enzyme replacement therapies
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
